Peter Ruf Selected Research

Peter Ruf Research Topics

17	Neoplasms (Cancer) 10/2021 - 02/2004
7	Melanoma (Melanoma, Malignant) 01/2017 - 02/2004
3	Ascites 01/2012 - 05/2010
2	Carcinoma (Carcinomatosis) 01/2012 - 05/2010
1	Non-Muscle Invasive Bladder Neoplasms 09/2021
1	Neuroblastoma 01/2021
1	Ovarian Neoplasms (Ovarian Cancer) 12/2015
1	Disease Progression 12/2015
1	Lymphoma (Lymphomas) 05/2010
1	Breast Neoplasms (Breast Cancer) 05/2009
1	Graft vs Host Disease (Graft-Versus-Host Disease) 08/2008
1	Residual Neoplasm 08/2008

7	catumaxomabIBA 10/2021 - 05/2010
7	Bispecific AntibodiesIBA 01/2017 - 09/2008
6	Epithelial Cell Adhesion MoleculeIBA 10/2021 - 08/2008
6	AntibodiesIBA 01/2021 - 02/2004
5	AntigensIBA 01/2021 - 02/2004
4	Immunoglobulin G (IgG)IBA 01/2021 - 05/2010
3	Immunoglobulin Fc FragmentsIBA 01/2021 - 08/2012
3	CytokinesIBA 01/2021 - 02/2004
3	GangliosidesIBA 11/2012 - 02/2004
2	GD2 gangliosideIBA 08/2015 - 08/2012
2	ertumaxomabIBA 05/2010 - 05/2009
1	Cytostatic AgentsIBA 09/2021
1	dinutuximabIBA 01/2021
1	Surface Antigens (Surface Antigen)IBA 01/2021
1	IpilimumabIBA 01/2017
1	Immune Checkpoint InhibitorsIBA 01/2017
1	DNA (Deoxyribonucleic Acid)IBA 12/2015
1	9-O-acetyl-GD3 gangliosideIBA 11/2012
1	Peptides (Polypeptides)IBA 08/2012
1	InterferonsIBA 08/2012
1	Immunoglobulins (Immunoglobulin)IBA 01/2012
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2012
1	Hepatitis B e AntigensIBA 05/2010
1	human ERBB2 proteinIBA 05/2009
1	Trastuzumab (Herceptin)FDA Link 05/2009
1	InterleukinsIBA 08/2008
1	Proteoglycans (Proteoglycan)IBA 02/2004
1	PerforinIBA 02/2004

7	Therapeutics 09/2021 - 02/2004
3	Immunotherapy 08/2015 - 08/2012
1	Intravesical Administration 09/2021
1	Intravenous Administration 08/2015
1	Aftercare (After-Treatment) 01/2012